Tirzepatide remains the reference molecule for protocols that need the deepest published evidence base today
(USA), for the treatment of various cancers
Discontinuation and weight regain How often people stop the medication TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo 2 TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo 3 Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo 1 For comparison, Wegovys STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaros SURMOUNT-1 reported a similar rate
(5) Bonus points : Its always a good idea to consider overall patterns, not just individual foods
In other words, until youve turned over your data
In this critical review, we will present the latest findings on underlying molecular and pathophysiological mechanisms in the development of liver fibrosis and their utilization as potential therapeutic targets, as shown in Fig